A case of protracted eosinopenia after a single subcutaneous dose of benralizumab

Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147–74. https://doi.org/10.1146/annurev.immunol.24.021605.090720. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin‑5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199–204. https://doi.org/10.1164/rccm.200208-789OC. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL‑5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344–1353e2. https://doi.org/10.1016/j.jaci.2010.04.004. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL‑5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125:1237–1244e2. https://doi.org/10.1016/j.jaci.2010.04.005. Martinez-Rivera C, Garcia-Olive I, Urrutia-Royo B, Basagana-Torrento M, Rosell A, Abad J. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis. BMC Pulm Med. 2021;21:35. https://doi.org/10.1186/s12890-021-01397-7.